FBRX - NASDAQ
Forte Biosciences, Inc.
$16.69
-8.2%Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
At a Glance
Live Snapshotfbrx
Common Stock
Last Annual Value
13.00K
3-Year CAGR
-15%
5-Year CAGR
%
10-Year CAGR
21%
Forte Biosciences, Inc. Competitors Analysis of Common Stock
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Forte Biosciences, Inc. NASDAQ:FBRX | 13.00K | -28.8% | -2.8% | 20.6% | |
 Nkarta, Inc. NASDAQ:NKTX | 7.00K | 11.9% | 18.5% | N/A | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 7.00K | 20.5% | 11.8% | 8.6% | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 10.00K | -58.0% | -35.8% | -12.9% | |
 Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP | 13.00K | -39.6% | -51.7% | 12.5% | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 23.00 | 125.7% | N/A | N/A | |
 Applied Therapeutics, Inc. NASDAQ:APLT | 35.00K | 63.6% | 63.5% | N/A | |
 Fate Therapeutics, Inc. NASDAQ:FATE | 115.00K | 5.1% | 3.7% | 10.9% | |
 PepGen Inc. NASDAQ:PEPG | 7.00K | 51.8% | N/A | N/A | |
 Alector, Inc. NASDAQ:ALEC | 11.00K | 11.2% | 6.6% | N/A | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 2.00K | N/A | -30.7% | -7.7% |
Forte Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your FBRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.